Quantcast

Latest Tenofovir Stories

2010-07-28 07:35:00

RESEARCH TRIANGLE PARK, N.C., July 28 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate...

2010-07-26 07:30:00

TITUSVILLE, N.J., July 26 /PRNewswire/ -- Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S.

2010-07-22 07:30:00

VIENNA, July 22 /PRNewswire/ -- Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.

2010-07-19 15:31:00

CAPRISA 004 trial shows moderate protection against transmission of virus JOHANNESBURG and WASHINGTON, July 19 /PRNewswire-USNewswire/ -- Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria.

2010-07-19 15:10:00

WASHINGTON, July 19 /PRNewswire-USNewswire/ -- USAID Administrator Rajiv Shah released the following statement on today's historic CAPRISA 004 trial results: (Logo: http://photos.prnewswire.com/prnh/20091022/USAIDLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20091022/USAIDLOGO) USAID is proud to be the major funder of the first-ever proof of concept that a microbicide can effectively and safely reduce the transmission of HIV from men to vulnerable women.

2010-07-19 13:55:00

VIENNA, July 19 /PRNewswire-USNewswire/ -- "This is a historic day for HIV prevention research.

2010-06-17 06:00:00

HAIKOU, China, June 17 /PRNewswire-Asia/ -- Kun Run Biotechnology, Inc. (the "Company" or "Kun Run") (OTC Bulletin Board: KURU), a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA). Entecavir is an oral antiviral drug used in the treatment of Hepatitis-B infection.

2010-06-02 07:00:00

WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of HIV, Gilead and Tibotec (a wholly owned subsidiary of Johnson & Johnson) remain on track to launch three novel treatment options in the next two years - Gilead's Quad (a four drug, one pill, once-daily, regimen), Tibotec's rilpivirine and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir fixed-dose...

2010-05-24 13:19:33

New research presented at International Microbicides Conference.


Word of the Day
quotha
  • Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.
The word 'quotha' is an alteration of 'quoth he'.
Related